AbbVie expects $2.7 billion R&D charge in third quarter

(Reuters) -Drugmaker AbbVie in a regulatory filing on Friday said it expects third-quarter earnings to include a $2.7 billion charge related to in-process research and development (IPR&D) expenses. The drugmaker also forecast third-quarter adjusted earnings per share in the range of $1.74 to $1.78, according to the filing. (Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)